| Name | Title | Contact Details |
|---|
We are the leading, global mid-sized contract research organization. Our team of more than 4,200 employees working across 47 countries delivers collaborative clinical development services and solutions Designed Around You®.
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings. All of FibroGen`s therapeutic candidates have been internally developed based on FibroGen`s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).
T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.
Lumosity is an online program consisting of games claiming to improve memory, attention, flexibility, speed of processing, and problem solving.
Black and Black Surgical is a Tucker, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.